Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar & Na...
January 18 2018 - 9:00AM
Business Wire
Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a
commercial stage natural-products pharmaceuticals company focused
on developing novel, sustainably derived gastrointestinal products
for both human prescription use and animals on a global basis,
announced today that Company management will host a conference call
on Monday, January 22, 2018 at 4:15 p.m. Eastern Time to provide
updates regarding Jaguar and Napo Pharmaceuticals commercial,
educational and product development activities and 2017 results.
Napo Pharmaceuticals, Inc. (Napo), Jaguar’s wholly-owned
subsidiary, focuses on human health and the ongoing
commercialization of, and development of follow-on indications for,
Mytesi® (crofelemer), Napo’s first-in-class, FDA-approved
anti-secretory human prescription drug.
Conference Call Dial-In Instructions
Investors interested in listening to the live call should dial
800-239-9838 (U.S. Toll Free), 323-794-2551 (International). Please
ask the operator to connect you to the call or provide the
conference ID number: 1066868. A live webcast of the conference
call will be available online which can be accessed on the investor
relations section of the Jaguar website (click here). Please allow
extra time prior to the call to visit the site and download any
necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a
replay of the webcast will be available on the investor relations
section of Jaguar’s website (click here) for 90 days following the
call. Also, a dial-in replay of the call will be available through
February 5, 2018, at 844-512-2921 (U.S. Toll Free) or 412-317-6671
(International). Participants must use the following code to access
the dial-in replay of the call: 1066868.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated
for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi®. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and
their disease may worsen. In clinical studies, the most common
adverse reactions occurring at a rate greater than placebo were
upper respiratory tract infection (5.7%), bronchitis (3.9%), cough
(3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are
available at Mytesi.com. Crofelemer, the active ingredient in
Mytesi®, is a botanical (plant-based) drug extracted and purified
from the red bark sap of the medicinal Croton lechleri tree in the
Amazon rainforest. Napo has established a sustainable harvesting
program for crofelemer to ensure a high degree of quality and
ecological integrity.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage natural-products
pharmaceuticals company focused on developing novel, sustainably
derived gastrointestinal products for both human prescription use
and animals on a global basis. Our wholly-owned subsidiary, Napo
Pharmaceuticals, Inc., focuses on developing and commercializing
proprietary human gastrointestinal pharmaceuticals for the global
marketplace from plants used traditionally in rainforest areas. Our
Mytesi® (crofelemer) product is approved by the U.S. FDA for the
symptomatic relief of noninfectious diarrhea in adults with
HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
planned, potential follow-on indications for Mytesi®. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this release are only predictions. Jaguar has based
these forward-looking statements largely on its current
expectations and projections about future events. These
forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise
any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances
or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180118005502/en/
Jaguar Health, Inc.Peter Hodgephodge@jaguar.health
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jul 2023 to Jul 2024